ES2187785T3 - 3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales. - Google Patents

3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales.

Info

Publication number
ES2187785T3
ES2187785T3 ES97928269T ES97928269T ES2187785T3 ES 2187785 T3 ES2187785 T3 ES 2187785T3 ES 97928269 T ES97928269 T ES 97928269T ES 97928269 T ES97928269 T ES 97928269T ES 2187785 T3 ES2187785 T3 ES 2187785T3
Authority
ES
Spain
Prior art keywords
difenil
triazols
substituted
burners
metal burners
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97928269T
Other languages
English (en)
Inventor
Rene Lattmann
Pierre Acklin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4214048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2187785(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis AG filed Critical Novartis AG
Application granted granted Critical
Publication of ES2187785T3 publication Critical patent/ES2187785T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/04—Chelating agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

LOS 3,5 - DIFENIL - 1,2,4 - TRIAZOLES DE FORMULA (I) TIENEN PROPIEDADES FARMACEUTICAS UTILES Y SON PARTICULARMENTE ACTIVOS COMO QUELADORES DEL HIERRO. PUEDEN USARSE PARA EL TRATAMIENTO DE UNA SOBRECARGA DE HIERRO EN EL ORGANISMO DE ANIMALES DE SANGRE CALIENTE. ALGUNOS DE ESTOS COMPUESTOS SON NUEVOS.
ES97928269T 1996-06-25 1997-06-24 3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales. Expired - Lifetime ES2187785T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH159396 1996-06-25

Publications (1)

Publication Number Publication Date
ES2187785T3 true ES2187785T3 (es) 2003-06-16

Family

ID=4214048

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97928269T Expired - Lifetime ES2187785T3 (es) 1996-06-25 1997-06-24 3,5-difenil-1,2,4-triazoles sustituidos y su uso como queladores farmaceuticos de metales.

Country Status (36)

Country Link
US (3) US6465504B1 (es)
EP (1) EP0914118B1 (es)
JP (1) JP3541042B2 (es)
KR (1) KR100616378B1 (es)
CN (1) CN1146415C (es)
AP (1) AP1127A (es)
AR (1) AR007479A1 (es)
AT (1) ATE226435T1 (es)
AU (1) AU718037B2 (es)
BG (1) BG64248B1 (es)
BR (1) BR9709973A (es)
CA (1) CA2255951C (es)
CY (2) CY2429B1 (es)
CZ (1) CZ291470B6 (es)
DE (3) DE122007000020I1 (es)
DK (1) DK0914118T3 (es)
ES (1) ES2187785T3 (es)
FR (1) FR06C0049I2 (es)
GE (1) GEP20084355B (es)
HU (1) HU226232B1 (es)
IL (1) IL127212A0 (es)
LT (1) LTC0914118I2 (es)
LU (1) LU91291I2 (es)
MY (1) MY129541A (es)
NL (1) NL300248I2 (es)
NO (3) NO317180B1 (es)
NZ (1) NZ333308A (es)
OA (1) OA10946A (es)
PL (1) PL194758B1 (es)
PT (1) PT914118E (es)
RU (1) RU2208010C2 (es)
SI (1) SI0914118T1 (es)
SK (1) SK284319B6 (es)
TR (1) TR199802693T2 (es)
TW (1) TW533205B (es)
WO (1) WO1997049395A1 (es)

Families Citing this family (109)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6677487B2 (en) 2001-08-30 2004-01-13 Pharmacia Corporation α-haloenamine reagents
GB0126618D0 (en) * 2001-11-06 2002-01-02 Novartis Ag Organic compounds
ES2192494B1 (es) * 2002-03-27 2005-02-16 Consejo Superior De Investigaciones Cientificas Derivados de 1,2,4-triazol con propiedades cannabinoides.
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
GB0223978D0 (en) * 2002-10-15 2002-11-20 Novartis Ag Organic compound
MY142651A (en) * 2003-03-18 2010-12-15 Merck Sharp & Dohme Biaryl substituted triazoles as sodium channel blockers
US20050008699A1 (en) * 2003-07-11 2005-01-13 Fred Wehling Effervescent glucosamine composition
AU2004289694B2 (en) * 2003-11-10 2010-05-13 Merck Sharp & Dohme Corp. Substituted triazoles as sodium channel blockers
CN1889952A (zh) * 2003-12-19 2007-01-03 诺瓦提斯公司 (a)N－{5－[4－(4－甲基－(哌嗪－1－基)－甲基)－苯甲酰胺基]－2－甲基苯基}－4－(3－吡啶基)－2－嘧啶－胺和( b )至少一种羟丁赖氨酸形成抑制剂的组合产品及其用途
GB0408078D0 (en) * 2004-04-08 2004-05-12 Novartis Ag Organic compounds
US9737511B2 (en) * 2004-05-24 2017-08-22 Geoffrey C. GURTNER Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
CA2568134A1 (en) * 2004-05-24 2005-12-08 New York University Method of treating or preventing pathologic effects of acute increases in hyperglycemia and/or acute increases of free fatty acid flux
PT1843771E (pt) * 2005-01-28 2011-12-02 Novartis Ag Uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação da atividade da cinase tie-2
CN101111237A (zh) * 2005-02-10 2008-01-23 诺瓦提斯公司 改善药物处置的方法
CA2608709A1 (en) * 2005-05-31 2006-12-07 Novartis Ag Treatment of liver diseases in which iron plays a role in pathogenesis
NZ567155A (en) * 2005-10-19 2010-06-25 Novartis Ag Dispersible tablets comprising deferasirox
PL1945272T3 (pl) 2005-11-01 2014-03-31 Novartis Ag Sposób prowadzenia scyntygraffi
PL1988083T3 (pl) * 2006-02-03 2014-08-29 Taisho Pharmaceutical Co Ltd Pochodna triazolowa
JP2009536180A (ja) * 2006-05-09 2009-10-08 ノバルティス アクチエンゲゼルシャフト 鉄キレート剤と抗新生物剤を含む組合せ剤およびそれらの使用
JP2009538329A (ja) 2006-05-23 2009-11-05 ノバルティス・アクチェンゲゼルシャフト 遺伝性ヘモクロマトーシスの処置方法
TWI448285B (zh) * 2006-07-13 2014-08-11 Los Angeles Biomed Res Inst 用以治療白黴菌症（ｍｕｃｏｒｍｙｃｏｓｉｓ）及其他真菌類疾病之組合物及方法
CN101500561A (zh) * 2006-08-04 2009-08-05 诺瓦提斯公司 应用铁螯合剂治疗内分泌功能障碍
RU2339625C2 (ru) * 2006-11-02 2008-11-27 Российский химико-технологический университет (РХТУ им. Д.И. Менделеева) ЗАМЕЩЕННЫЕ N-[ω-АЗОЛ-1-ИЛ)АЛКИЛ]БЕНЗОЛСУЛЬФАМИДЫ В КАЧЕСТВЕ СРЕДСТВ С АНТИАГРЕГАЦИОННОЙ АКТИВНОСТЬЮ И СПОСОБЫ ИХ ПОЛУЧЕНИЯ
EP1927591A1 (en) * 2006-11-29 2008-06-04 Novartis AG Polymorphic Forms of Deferasirox (ICL670)
CA2670313C (en) 2006-11-29 2013-02-12 Novartis Ag Polymorphic forms of deferasirox (icl670a)
EP2108013A2 (en) * 2007-01-29 2009-10-14 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Crystalline forms of deferasirox
KR20100016512A (ko) * 2007-05-14 2010-02-12 노파르티스 아게 심근경색증 치료를 위한 철 킬레이터의 용도
EP1994930A1 (en) * 2007-05-22 2008-11-26 Novartis AG Triazol compounds for treating biofilm formation
WO2009016359A1 (en) * 2007-07-27 2009-02-05 Pliva Hrvatska D.O.O. New forms of deferasirox
US20090082412A1 (en) * 2007-09-26 2009-03-26 Protia, Llc Deuterium-enriched deferasirox
EP2062572A1 (en) 2007-11-19 2009-05-27 Teva Pharmaceutical Industries Ltd. Pharmaceutical compositions
CZ301873B6 (cs) 2008-01-30 2010-07-14 Farmak, A. S. Zpusob prípravy kyseliny 4-[3,5-bis(2-hydroxyfenyl)-[1,2,4]triazol-1-yl]benzoové
WO2009106824A2 (en) * 2008-02-25 2009-09-03 Cipla Limited Pharmaceutical formulations
WO2009111611A2 (en) 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
EP2291360A2 (en) * 2008-04-21 2011-03-09 Actavis Group PTC ehf. Solid state forms of deferasirox salts and process for the preparation thereof
WO2009147529A1 (en) * 2008-06-02 2009-12-10 Actavis Group Ptc Ehf Substantially pure deferasirox and processes for the preparation thereof
JPWO2010032489A1 (ja) 2008-09-22 2012-02-09 国立大学法人旭川医科大学 鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
US10098857B2 (en) 2008-10-10 2018-10-16 The Board Of Trustees Of The Leland Stanford Junior University Topical and transdermal delivery of HIF-1 modulators to prevent and treat chronic wounds
WO2010092419A1 (en) 2009-02-12 2010-08-19 Assistance Publique - Hopitaux De Paris Combined treatment of multiple sclerosis
JP2012520878A (ja) 2009-03-19 2012-09-10 ロサンゼルス ビオメドイカル リサーチ インストイトウテ アト ハルボル‐ユーシーエルエー メドイカル センテル ムコール菌症、及びその他の真菌疾患の治療のためのワクチン組成物、及び方法
IT1398770B1 (it) * 2009-07-22 2013-03-18 Bellacchio Oligonucleotidi attivabili mediante l'appaiamento con sequenze di acidi nucleici e loro uso
WO2011021218A2 (en) * 2009-08-12 2011-02-24 Msn Laboratories Limited Process for the preparation of 4-[3,5-bis(2-hydroxyphenyl)-1h-1,2,4-triazol-1-yl]-benzoic acid and its amine salts
BR112012013710A2 (pt) * 2009-12-07 2015-09-15 Mapi Pharma Ltd processos para a preparação de deferasirox e polimorfos de deferasirox.
CA2805568A1 (en) 2010-07-08 2012-01-12 Ratiopharm Gmbh Oral dosage form of deferasirox
WO2012025935A2 (en) 2010-08-25 2012-03-01 Ramamohan Rao Davuluri A process for the preparation of 2-(2-hydroxyphenyl)-benz[1,3]oxazin-4-one and its use for preparation of 4-[3, 5-bis (2-hydroxyphenyl)-1h-1, 2, 4-triazol-1-yl] benzoic acid
PE20140166A1 (es) * 2010-10-01 2014-02-17 Cipla Ltd Composicion farmaceutica que comprende deferasirox
EP2643306B1 (en) * 2010-11-24 2015-09-23 Alembic Pharmaceuticals Limited Process for the preparation of deferasirox
WO2012096183A1 (ja) 2011-01-14 2012-07-19 株式会社ダステック 高分子鉄キレート剤
US20140316534A1 (en) 2011-10-14 2014-10-23 Photocure Asa Stent
US20140276107A1 (en) 2011-10-14 2014-09-18 Photocure Asa Photodynamic diagnosis
US8822464B2 (en) 2011-11-28 2014-09-02 Boehringer Ingelheim International Gmbh N-aryl-piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8741892B2 (en) 2011-12-05 2014-06-03 Boehringer Ingelheim International Gmbh Compounds
US8642774B2 (en) * 2011-12-08 2014-02-04 Boehringer Ingelheim International Gmbh Compounds
US8846948B2 (en) 2011-12-13 2014-09-30 Boehringer Ingelheim International Gmbh Compounds
US8796467B2 (en) 2011-12-13 2014-08-05 Boehringer Ingelheim International Gmbh Compounds
US8883789B2 (en) 2011-12-14 2014-11-11 Boehringer Ingelheim International Gmbh Piperazine derivatives and their use as positive allosteric modulators of mGluR5 receptors
US8716277B2 (en) 2011-12-14 2014-05-06 Boehringer Ingelheim International Gmbh Substituted imidazole compounds useful as positive allosteric modulators of mGlu5 receptor activity
US8937176B2 (en) 2011-12-14 2015-01-20 Boehringer Ingelheim International Gmbh Compounds
US8889677B2 (en) 2012-01-17 2014-11-18 Boehringer Ingellheim International GmbH Substituted triazoles useful as mGlu5 receptor modulators
NO2964659T3 (es) * 2013-03-06 2018-01-06
HUE036921T2 (hu) * 2013-03-08 2018-08-28 Novartis Ag Orális deferasirox készítmények
RU2015149544A (ru) * 2013-05-10 2017-06-16 Сипла Лимитед Низкодозовая фармацевтическая композиция
DE102013217390A1 (de) 2013-09-02 2015-03-05 Henkel Ag & Co. Kgaa Wasch- und Reinigungsmittel mit verbesserter Leistung
CN103454370B (zh) * 2013-09-11 2014-12-24 中美华世通生物医药科技（武汉）有限公司 一种利用hplc测定原料药中苯肼类化合物残留的方法
UA122479C2 (uk) 2014-01-24 2020-11-25 Дана-Фарбер Кенсер Інстітьют, Інк. Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1)
PL3099717T3 (pl) 2014-01-31 2019-10-31 Novartis Ag Cząsteczki przeciwciała dla TIM-3 i ich zastosowanie
EA201691765A1 (ru) 2014-03-14 2016-12-30 Новартис Аг Молекулы антител против lag-3 и их применения
EP2946771B1 (en) 2014-05-20 2019-03-20 Sanovel Ilac Sanayi ve Ticaret A.S. Water-dispersible tablet formulation comprising deferasirox
EP2987482A1 (en) 2014-08-22 2016-02-24 Santa Farma Ilaç Sanayi A.S. Soluble and dispersible pharamaceutical deferasirox formulation
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
SG11201702401RA (en) 2014-10-14 2017-04-27 Novartis Ag Antibody molecules to pd-l1 and uses thereof
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
KR20160088965A (ko) 2015-01-16 2016-07-27 대원제약주식회사 데페라시록스를 함유하는 현탁제
TWI706958B (zh) 2015-03-10 2020-10-11 美商艾杜諾生物科技公司 活化「干擾素基因刺激因子」依賴性訊息傳導之組合物及方法
CN104817538A (zh) * 2015-03-13 2015-08-05 东南大学 去铁斯诺-他克林金属离子鳌合剂及其药物用途
WO2016167729A1 (en) 2015-04-16 2016-10-20 Öğün Yusuf Toktamiş Dispersible tablets comprising deferasirox
EP3095443A1 (en) 2015-05-21 2016-11-23 Abdi Ibrahim Ilac Sanayi ve Ticaret A.S. Pharmaceutical composition comprising deferasirox
WO2016203488A1 (en) * 2015-06-16 2016-12-22 Havaldar Freddy H Preparation of novel deferasirox analogues for antimalarial activity
US20180340025A1 (en) 2015-07-29 2018-11-29 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3328418A1 (en) 2015-07-29 2018-06-06 Novartis AG Combination therapies comprising antibody molecules to pd-1
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
KR101695970B1 (ko) 2015-07-31 2017-01-13 건일제약 주식회사 데페라시록스 함유 산제 및 그 제조방법
CN106554770B (zh) * 2015-09-29 2018-10-19 杭州杜易科技有限公司 一种三唑衍生物金属离子荧光探针及其制备方法和应用
WO2017068089A2 (en) 2015-10-23 2017-04-27 Vifor (International) Ag Novel ferroportin inhibitors
CN108495651A (zh) 2015-12-17 2018-09-04 诺华股份有限公司 抗pd-1的抗体分子及其用途
WO2017158559A1 (en) 2016-03-17 2017-09-21 Lupin Limited Compositions of deferasirox
EP3507367A4 (en) 2016-07-05 2020-03-25 Aduro BioTech, Inc. CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF
EP3518904A1 (en) 2016-09-30 2019-08-07 Synthon B.V. Pharmaceutical composition comprising deferasirox
JOP20180036A1 (ar) 2017-04-18 2019-01-30 Vifor Int Ag أملاح لمثبطات فروبورتين جديدة
UY37695A (es) 2017-04-28 2018-11-30 Novartis Ag Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
CZ2017255A3 (cs) 2017-05-04 2018-11-14 Zentiva, K.S. Filmem potažené tablety Deferasiroxu
WO2018208242A1 (en) 2017-05-10 2018-11-15 İlko Ilaç Sanayi Ve Ticaret Anonim Şirketi Formulation of deferasirox tablet for oral suspension composition with better processability
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
US11331288B2 (en) 2017-09-14 2022-05-17 The Board Of Trustees Of The Leland Stanford Junior University Conditioning irradiated tissue for increasing vascularity
EP3489692A1 (de) 2017-11-28 2019-05-29 Siemens Healthcare Diagnostics Products GmbH Prothrombinzeit-reagenz enthaltend einen eisenchelator
TR201722910A2 (tr) 2017-12-29 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deferasi̇roks i̇çeren suda dağilabi̇len tablet formülasyonlari
KR20190110771A (ko) 2018-03-21 2019-10-01 주식회사 한국팜비오 데페라시록스를 함유하는 소형 분산성 정제
CN108727287B (zh) * 2018-05-10 2020-10-27 东南大学 1,2,4-三唑类化合物及其盐和应用
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
GR1009592B (el) * 2018-07-03 2019-09-11 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν χηλικο παραγοντα συμπλεκτικο του σιδηρου και μεθοδος για την παρασκευη αυτου
KR20200113116A (ko) 2019-03-22 2020-10-06 주식회사 한국팜비오 데페라시록스를 포함하는 필름코팅정제
TW202102478A (zh) 2019-04-01 2021-01-16 瑞士商威佛（國際）股份有限公司 新穎的鐵螯合物
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
IT202000000922A1 (it) 2020-01-20 2021-07-20 Cage Chemicals S R L Complessi di ferro e relativi sali come agenti di contrasto per MRI
US11155547B1 (en) * 2020-06-18 2021-10-26 Alterity Therapeutics Limited Compounds for and methods of treating diseases
WO2022186809A1 (en) 2021-03-05 2022-09-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi The film coated tablet comprising deferasirox
CN114276305B (zh) * 2021-12-28 2023-11-17 中山大学 一种三取代苯基-1,2,4-三氮唑衍生物及其制备和治疗神经元损伤的应用
CN114478410B (zh) * 2022-03-31 2022-11-29 中山大学 一种二取代苯基-1,2,4-三氮唑衍生物及其制备和应用
CN114591254B (zh) * 2022-03-31 2023-10-13 中山大学 一种3,5-二取代苯基-1,2,4-三氮唑衍生物及其制备方法和应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH84663A4 (es) 1963-01-24 1964-11-14
DE2628152C2 (de) 1976-06-23 1985-03-28 Bayer Ag, 5090 Leverkusen Fungizide und nematizide Mittel
US4528196A (en) * 1981-02-23 1985-07-09 The United States Of America As Represented By The Department Of Health And Human Services Chelating agents for the treatment of iron overload
SU1280851A1 (ru) * 1983-07-08 1996-05-27 Ростовский государственный университет 1-фенил-3-алкил-5-(o-оксифенил)-1,2,4-триазолы, обладающие транквилизирующим и антигипоксическим действием, и 1-фенил-3-н-бутил-5-(о-оксифенил)-1,2,4-триазол, обладающий транквилизирующим, антигипоксическим и анальгетическим действием
GB8429307D0 (en) 1984-11-20 1984-12-27 Shell Int Research Heterocyclic herbicides
IL84331A0 (en) * 1987-11-02 1988-04-29 Yissum Res Dev Co Pyridoxyl hydrazone derivatives and pharmaceutical compositions containing the same
US5260322A (en) 1990-10-08 1993-11-09 Merck & Co., Inc. Angiotension II antagonists in the treatment of hyperuricemia
DE4320801A1 (de) * 1993-06-23 1995-01-05 Fahlberg List Pharma Gmbh 2-Hydroxyphenylsubstituierte 1,2,4-Triazole und 1,2,4-Oxadiazole, ihre Verwendung als pharmazeutische Wirkstoffe und sie enthaltende Arzneimittel

Also Published As

Publication number Publication date
LU91291I2 (fr) 2007-01-29
RU2208010C2 (ru) 2003-07-10
TR199802693T2 (xx) 1999-05-21
KR20050098029A (ko) 2005-10-10
NO986024D0 (no) 1998-12-21
LU91291I9 (es) 2018-12-27
CN1223579A (zh) 1999-07-21
OA10946A (en) 2003-02-27
CY2429B1 (en) 2004-11-12
LTPA2007001I1 (lt) 2018-06-25
BG103003A (en) 1999-09-30
NO2006017I1 (no) 2006-12-18
CA2255951C (en) 2006-10-10
NO2018014I1 (no) 2018-04-17
PT914118E (pt) 2003-02-28
NO2006017I2 (no) 2011-07-04
ATE226435T1 (de) 2002-11-15
CN1146415C (zh) 2004-04-21
NO2018014I2 (no) 2018-11-19
NO986024L (no) 1998-12-21
HU226232B1 (en) 2008-07-28
JP3541042B2 (ja) 2004-07-07
US6723742B2 (en) 2004-04-20
GEP20084355B (es) 2008-04-29
US6596750B2 (en) 2003-07-22
CZ427298A3 (cs) 1999-03-17
NO317180B1 (no) 2004-09-06
EP0914118A1 (en) 1999-05-12
NL300248I1 (nl) 2007-02-01
CA2255951A1 (en) 1997-12-31
CZ291470B6 (cs) 2003-03-12
DE69716602T2 (de) 2003-06-26
US20030069273A1 (en) 2003-04-10
PL330119A1 (en) 1999-04-26
TW533205B (en) 2003-05-21
FR06C0049I2 (fr) 2007-04-27
KR100616378B1 (ko) 2006-08-28
DE122007000020I1 (de) 2007-05-24
US6465504B1 (en) 2002-10-15
CY2007005I1 (el) 2010-07-28
DE69716602D1 (de) 2002-11-28
FR06C0049I1 (es) 2007-03-09
BR9709973A (pt) 1999-08-10
CY2007005I2 (el) 2018-12-12
DE122007000020I2 (de) 2010-12-30
SK178598A3 (en) 1999-06-11
DK0914118T3 (da) 2003-02-24
SK284319B6 (sk) 2005-01-03
AR007479A1 (es) 1999-10-27
AU718037B2 (en) 2000-04-06
NL300248I2 (nl) 2007-03-01
AP1127A (en) 2002-12-06
HUP9903111A2 (hu) 2000-01-28
PL194758B1 (pl) 2007-07-31
EP0914118B1 (en) 2002-10-23
WO1997049395A1 (en) 1997-12-31
MY129541A (en) 2007-04-30
HUP9903111A3 (en) 2000-06-28
SI0914118T1 (en) 2003-04-30
BG64248B1 (bg) 2004-07-30
AU3262997A (en) 1998-01-14
AP9801407A0 (en) 1998-12-31
NZ333308A (en) 2000-05-26
IL127212A0 (en) 1999-09-22
LTC0914118I2 (lt) 2018-12-27
HK1020530A1 (en) 2000-05-12
JP2000507601A (ja) 2000-06-20
US20030203954A1 (en) 2003-10-30

Similar Documents

Publication Publication Date Title
ES2186015T3 (es) Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol.
ES2167377T3 (es) Derivados de piridina farmacologicamente activos y procedimientos para la preparacion de los mismos.
ES2174465T3 (es) Compuestos triazol y su utilizacion como ligandos de dopamina-d.
FI953748A0 (fi) Yhdisteitä, joilla on sekä voimakas kalsium antagonisti- että antioksidanttiaktiivisuus sekä niiden käyttö solua suojaavina aineina
ES2157027T3 (es) Oxazolidinonas sustituidas y su uso como farmacos antibacterianos.
SV1999000016A (es) Derivados de 2-(purin-9-il-tetrahidrofuran-3,4-diol ref. pg3443/sv
DE69725825D1 (de) 5-HT1F-Agonisten
DE10085007T1 (de) Antiinfektionszusammensetzungen zur Behandlung von erkranktem Gewebe, wie Lippenherpes
MX9207074A (es) Piperazinil- y piperidinil -ciclohexanoles y composicion farmaceutica que los comprende
NO983189L (no) Nye substituerte imidazolforbindelser
PT1263725E (pt) Novos compostos
CA2255951A1 (en) Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators
MX9700557A (es) Dihidrobenzofuranos.
EA200200097A1 (ru) Имидазоимидазолы и триазолы в качестве противовоспалительных агентов
ECSP055609A (es) "Uso de inhibidores de la IkB-quinasa para el tratamiento del dolor"
CY1114133T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ γ-ΦΑΙΝΥΛ-Δ-ΛΑΚΤΑΜΕΣ ΚΑΙ ΧΡΗΣΕΙΣ ΠΟΥ ΣΧΕΤΙΖΟΝΤΑΙ ΠΡΟΣ ΑΥΤΕΣ
EA200000911A1 (ru) Новые кристаллические формы антивирусного соединения бензимидазола
NZ513096A (en) Compositions for treating inflammatory response
DE69723863D1 (de) Chinoline und deren therapeutische verwendung
ATE276241T1 (de) Antioxidationsmittel
TR200200066T2 (tr) Migrenin tedavisi için seçici iGluR5 reseptör antagonistleri
TR199902334T2 (xx) Psikotik bozukluklar�n tedavisi veya profilaksisi i�in mirtazapin ve antipsikotik ajanlar�n yeni terap�tik kombinasyonlar�.
ES2101858T3 (es) Derivados de geneserina como inhibidores de colinesterasa.
DE60115466D1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
DE60129829D1 (de) Zyklisierte benzamid-neurokinin-antagonisten zur verwendung in therapie